Ucb S.a. · EURONEXT:UCB
Ucb — Investor Day (January 2023)
29 slides from Ucb's investor day presentation, Jan 9, 2023
Slide 1: Perspectives in Epilepsy Treatment and Care
UCB Current and Future Leadership Perspectives in Epilepsy Treatment and Care 9th January 2023 Proprietary and Confidential Property of UCB
Slide 2: Disclaimer and Safe Harbor
Disclaimer and Safe Harbor This presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking st
Slide 3: Our Global Epilepsy Leadership
Proprietary and Confidential Property of UCB Our Global Epilepsy Leadership Charl van Zyl Executive Vice President, Neurology Solutions & International Markets/Europe, UCB Proprietary and Confidential Property of UCB 3
Slide 4: Agenda
Antje Witte Welcome Head of Investor Relations, UCB Charl van Zyl Executive Vice President, UCB Our Epilepsy Leadership Neurology Solutions & Head of EU and International Markets Mike Davis Our Unified Epilepsy Strategy Proprietary and Confidential Property of UCB Head of Global Epilepsy, UCB Konrad
Slide 5: Our purpose: creating value for patients
Across UCB we are defined by our purpose: Creating value for patients now and into the future Proprietary and Confidential Property of UCB and sustainability is our business approach. We believe that everyone deserves to live the best life that they can - as free as possible from the challenges and
Slide 6: UCB Epilepsy Leadership Across the Globe
UCB Epilepsy Leadership Across the Globe UCB’s Portfolio of Epilepsy Solutions 1 million compounds per drug screening ~3.0M+ >500+ Proprietary and Confidential Property of UCB Epilepsy Patients Strategic Epilepsy Investments and Partnerships under care worldwide protein targets reviewed AI/digital p
Slide 7: Our Unified Epilepsy Strategy
Proprietary and Confidential Property of UCB Our Unified Epilepsy Strategy Mike Davis Head of Global Epilepsy, UCB Proprietary and Confidential Property of UCB 7
Slide 8: Evolved UCB's Organization
Evolved UCB’s Organization To Better Care for People Living with Epilepsy and Rare Syndromes Patient Outcomes and Portfolio Focus Experience DISEASE MODIFICATION DISEASE INTERACTION Innovation TREATING SYMPTOMS Proprietary and Confidential Property of UCB Moving patients towards underlying Broad Dig
Slide 9: Paradigm Shift from Seizure Suppression to Disease Modification
Paradigm Shift from Seizure Suppression to Disease Modification From Broad Populations to Expansion into Specific Populations with High Unmet Patient Needs Expression of Pathobiology Disease TODAY Novel SV2A and Na+ 1 Channel Agents Proprietary and Confidential Property of UCB UCB Leading Role Uncon
Slide 10: Epilepsy Innovation Strategy: Five Value Pools
Epilepsy Innovation Strategy Focused on Five Value Pools Projected arrival in market of innovation focus areas Disease Anti- epileptogenesis Improved chronic ASM’s modifying modification 1 Disease 4 5 • Optimize current portfolio through new formulations, indications and Proprietary and Confidential
Slide 11: Fintepla Provides a New Set of Answers in Rare Epilepsy Syndromes
Proprietary and Confidential Property of UCB FINTEPLA®▼ (fenfluramine oral solution) Provides a New Set of Answers in Rare Epilepsy Syndromes Konrad Werhahn, MD PhD Epileptologist & Head of Global Epilepsy Medical Affairs, UCB ▼This medicinal product is subject to additional monitoring. This will al
Slide 12: Fintepla Important Safety Information
Fintepla® Important Safety Information VALVULAR HEART DISEASE and PULMONARY ARTERIAL HYPERTENSION There is an association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine (the active ingredient in FINTEPLA), and valvular heart disease and pulmonary arterial hy
Slide 13: A parent's worst nightmare
“A parent’s worst nightmare” Developmental and epileptic encephalopathies: a group of rare, severe and complex epilepsies Typically occur in the infancy and early childhood Proprietary and Confidential Property of UCB ‸ High frequency of drug resistant seizures Associated with significant intellectu
Slide 14: Fenfluramine: Value of a Unique and Dual MoA
Fenfluramine: What is the Value of a Unique and Dual MoA? Antiseizure effects A. Epilepsy Anti-seizure effects mediated by multiple serotonergic receptors and sigma (σ) pathway activity • 5-HT1D, 5-HT2A, 5-HT2C receptors1,2 Proprietary and Confidential Property of UCB • Positive modulator of σ1 rece
Slide 15: Fenfluramine Offers New Hope for Individuals and Families Living with DEEs
Fenfluramine Offers New Hope for Individuals and Families Living with Challenging Developmental Epileptic Encephalopathies (DEEs) Dravet Syndrome (DS) Lennox-Gastaut Syndrome (LGS) CDKL5 Deficiency Disorder (CDD) ~12k-15k ~60k-100k ~8k-10k Proprietary and Confidential Property of UCB US, EU, JPN pre
Slide 16: Fenfluramine Creating Meaningful Value to Patients & HCPs
Fenfluramine Creating Meaningful Value to Patients & HCPs across Dravet & Lennox-Gastaut Syndrome Dravet Syndrome Lennox-Gastaut Syndrome Largest reduction in seizures associated with Profound seizure reduction in highest refractory Dravet Syndrome – 1st or 2nd line Proprietary and Confidential Prop
Slide 17: Fenfluramine – In Their Words
Fenfluramine – In Their Words “Fenfluramine has raised the bar for evaluating the efficacy of future therapies in Dravet syndrome, both for seizures and for critically important patient-centered outcomes ”2 “For the first time, it became possible for a large percentage of patients to achieve profoun
Slide 18: Fenfluramine Open-Label Extension (LGS)
Fenfluramine Open-Label Extension (LGS) Frequency Reduction by Seizure Subtype (based on N=247 patients entering Open-Label Extension study) GTCS Tonic Atonic Tonic-Atonic 0.0 -10.0 Proprietary and Confidential Property of UCB Median Percentage Change in Seizure Frequency* -20.0 -30.0 n=165 n=78 -40
Slide 19: Early Solutions: Novel Science and Human Pathobiology for Drug Targeting
Proprietary and Confidential Property of UCB Early Solutions Leveraging Novel Science and Human Pathobiology for Improved Drug Targeting in Epilepsy Stefanie Dedeurwaerdere, PhD Head of Epilepsy Discovery, UCB Proprietary and Confidential Property of UCB 19
Slide 20: How Could Treatments Become more Personalized?
How Could Treatments Become more Personalized? How to Develop Treatments Tailored to Disease Mechanisms and Pathobiology? Mechanisms of epilepsy subtypes and syndromes Proprietary and Confidential Property of UCB In many patients, seizures are still not well controlled! In many patients, seizures ar
Slide 21: Molecular Taxonomy – Focus on Etiology & Entry Points
Molecular Taxonomy – Focus on Etiology & Entry Points for Molecularly Targeted Treatments Complex Epilepsy- Known Single Point Seizures Root Cause of Epilepsy Symptomatic Curative Root Cause Proprietary and Confidential Property of UCB Somatic Mutations Unknown Epilepsy as Structural Monogenic Epile
Slide 22: UCB R&D Leveraging Human Pathobiology and Digital AI Framework
UCB R&D Leveraging Human Pathobiology and Digital AI Framework in Epilepsy UCB R&D Epilepsy Engine Biological knowledge- Identification of Target Proprietary and Confidential Property of UCB mRNA profiling of Disease relevance of disease disease regulatory models for transactional assessment & epile
Slide 23: Scientific Advances Combined with Digital Pathobiology Driving Discovery Pipeline
Scientific Advances Combined with Digital Pathobiology are Driving Discovery Pipeline Patient segmentation is based on a number of criteria… Multiple incubator projects The targeted population has to be identifiable based on NCE underlying pathobiology Proprietary and Confidential Property of UCB pr
Slide 24: UCB Late-Stage Pipeline in Neurology
UCB Late-Stage Pipeline in Neurology Addressing Unmet Medical Needs and Bringing Clinically-Meaningful Improvements to People Living with Epilepsy and Neuroinflammatory & Neurodegenerative Diseases PHASE 1 PHASE 2 PHASE 3 FILING zilucoplan (C5 inhibitor) Generalized myasthenia gravis rozanolixizumab
Slide 25: UCB Continued Leadership in Epilepsy
Proprietary and Confidential Property of UCB UCB Continued Leadership in Epilepsy Charl van Zyl Executive Vice President, Neurology Solutions & International Markets/Europe, UCB Proprietary and Confidential Property of UCB 25
Slide 26: Evolution of UCB's Epilepsy Pipeline into Precision Medicine
The Evolution of UCB’s Epilepsy Pipeline into Precision Medicine with the Continued Ambition for Curative Therapy Digitized End-to-End Model (Patient-centric Business) - from Discovery to Patients Commitment to Patients, Translational Medicine Proprietary and Confidential Property of UCB Research an
Slide 27: UCB Leading in Epilepsy
UCB Leading in Epilepsy Epilepsy remains a core pillar of UCB’s strategy to bring differentiated value to patients Proprietary and Confidential Property of UCB Elevating care for the patient populations we serve Innovating science for symptom suppression, disease modification and cure Leading the wi
Slide 28: Q&A
Antje Witte Head of Investor Relations, UCB Charl van Zyl Executive Vice President Neurology Solutions Proprietary and Confidential Property of UCB & Head of EU and International Markets Q&A Mike Davis Head of Global Epilepsy, UCB Konrad Werhahn, MD, PhD Head of Medical Affairs, Epileptologist, UCB
Slide 29: Thank you
Proprietary and Confidential Property of UCB Thank you Proprietary and Confidential Property of UCB 29